PDF
ePub
Citation
Print
Abstract
Background
Adiponectin is secreted from adipose tissue and plays an important role in the regulation of glycemia and insulin resistance. In this study, the relationship between adiponectin and the adiposity, body composition, insulin sensitivity, lipid profile were respectively examined in newly diagnosed type 2 diabetes.
Methods
Total 1993 were participated in the Korea Rural Genomic Cohort Study (Geumsan County). After a 12-hour overnight fast, all subjects underwent 75-g oral glucose tolerance test. 105 of those were studied as newly diagnosed type 2 diabetes. The body composition was analyzed by means of bioelectric impedance analysis and the insulin sensitivity was estimated by fasting insulin, HOMA-IR and QUICKI method, respectively.
Results
Adiponectin positively correlated with high-density lipoprotein cholesterol (r = 0.246, P < 0.05). Adiponectin inversely associated with waist circumference (r = -0.408, P < 0.01), triglyceride (r = -0.274, P < 0.05), ferritin (r = -0.260, P < 0.05), visceral fat (r = -0.248, P < 0.05), high sensitivity C-reactive protein (r = -0.228, P < 0.05) and body mass index (r = -0.225, P < 0.05). In multiple linear regression, waist circumference and high-density lipoprotein cholesterol were analyzed as independent variables of serum adiponectin.
Figures and Tables
Table 1
Baseline characteristics of the study subjects
Data were means ± SD. 2h-glucose and 2h-insulin represent glucose and insulin concentrations at 120 min after a glucose challenge. BMI, Body mass index; BP, blood pressure; HDL-cholesterol, high-density lipoprotein cholesterol; LDL-cholesterol, low-density lipoprotein cholesterol; baPWV, brachial-ankle pulse wave velocity; HOMA-IR, homeostasis model for insulin resistance; QUICKI, quantitative insulin sensitivity check index.
Table 2
Anthropometric and clinical characteristics of newly diagnosed diabetes according to BMI
Data were means ± SD. 2h-glucose and 2h-insulin represent glucose and insulin concentrations at 120 min after a glucose challenge. BMI, Body mass index; BP, blood pressure; HDL-cholesterol, high-density lipoprotein cholesterol; LDL-cholesterol, low-density lipoprotein cholesterol; baPWV, brachial-ankle pulse wave velocity; HOMA-IR, homeostasis model for insulin resistance; QUICKI, quantitative insulin sensitivity check index.
Table 3
Anthropometric and clinical characteristics by serum adiponectin concentrations tertile
Data were means ± SD. 2h-glucose and 2h-insulin represent glucose and insulin concentrations at 120 min after a glucose challenge. BMI, Body mass index; BP, blood pressure; HDL-cholesterol, high-density lipoprotein cholesterol; LDL-cholesterol, low-density lipoprotein cholesterol; baPWV, brachial-ankle pulse wave velocity; HOMA-IR, homeostasis model for insulin resistance; QUICKI, quantitative insulin sensitivity check index.
Table 4
Correlation between adiponectin and blood lipid, anthropometric variables, surrogate of insulin resistance in new diagnosed type 2 Diabetes
2h-glucose and 2h-insulin represent glucose and insulin concentrations at 120 min after a glucose challenge Data were means ± SD. 2h-glucose and 2h-insulin represent glucose and insulin concentrations at 120 min after a glucose challenge. BMI, Body mass index; BP, blood pressure; HDL-cholesterol, high-density lipoprotein cholesterol; LDL-cholesterol, low-density lipoprotein cholesterol; baPWV, brachial-ankle pulse wave velocity; HOMA-IR, homeostasis model for insulin resistance; QUICKI, quantitative insulin sensitivity check index. Data were Pearson's correlation(r) coefficients adjusted for age and sex and standardized Coefficeients(β) using multivariate regression analysis. *P < 0.01. **P < 0.05.
References
1. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 1996. 2:800–803.
2. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell. 1996. 87:377–389.
3. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y. PPARgamma ligands increase expression and plasma concent-rations of adiponectin, an adiposederived protein. Diabetes. 2001. 50:2094–2099.
4. Delporte ML, Funahashi T, Takahashi M, Matsuzawa Y, Brichard SM. Pre- and posttranslational negative effect of beta-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies. Biochem J. 2002. 367:677–685.
5. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2002. 290:1084–1089.
6. Mallamaci F, Zoccali C, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Adiponectin in essential hypertension. J Nephrol. 2002. 15:507–511.
7. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y. Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003. 23:85–89.
8. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000. 20:1595–1599.
9. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002. 87:2764–2769.
10. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care. 2003. 26:1745–1751.
11. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004. 27:Suppl 1. S5–S10.
12. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991. 14:173–194.
13. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes. 1994. 43:1271–1278.
14. Alwssi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible line between visceral fat accumulation and vascular disease. Diabetes. 1997. 46:860–867.
15. Yudkin JS, Kumari M, Humphries SE, Mohammed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000. 148:209–214.
16. Weyer C, Tataranni PA, Pratley RE. Insulin action and insulinemia are closely related to the fasting complement C3, but not acylationstimulating protein concentration. Diabetes Care. 2000. 23:779–785.
17. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Novel modulator for endothelial adhesion molecules: adipocyte derived plasma protein adiponectin. Circulation. 1999. 100:2473–2476.
18. Yokota T, Oritani K, Takahashi I, Ishikana J, Matsuyama A, Ouchi N, Kinara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the function of macrophages. Blood. 2000. 96:1723–1732.
19. Nishizawa T, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y. Androgens decrease plasma adiponectin, an insulin sensitizing adipocyte derived protein. Diabetes. 2002. 51:2734–2741.
20. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999. 257:79–83.
21. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectimia in obesity and type 2 diabetes: close association with insulin resistance and hyper-insulinemia. J Clin Endocrinol Metab. 2001. 86:1930–1935.
24. O'Neal DN, Dragicevic G, Rowley KG, Ansari MZ, Balazs N, Jenkins A, Best JD. A cross-sectional study of the effects of type 2 diabetes and other cardiovascular risk factors on structure and function of nonstenotic arteries of the lower limb. Diabetes Care. 2003. 26:199–205.
25. Yamashina A, Tomiyama H, Arai T, Hirose K, Koji Y, Hirayama Y, Yamamoto Y, Hori S. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res. 2003. 26:615–622.
26. Miyata M, Kubo T, Hashiguchi H, Fukudome M, Fukushige E, Koriyama N, Nakazaki M, Minagoe S, Tei C. Brachial-ankle pulse wave velocity is useful for evaluation of complications in type 2 diabetic patients. Hypertens Res. 2003. 26:807–813.
27. Yokoyama H, Hirasawa K, Aoki T, Ishiyama M, Koyama K. Brachial-ankle pulse wave velocity measured automatically by oscillometric method is elevated in diabetic patients with incipient nephropathy. Diabet Med. 2003. 20:942–945.
28. Yokoyama H, Shoji T, Kimoto E, Shinohara K, Tanaka S, Koyama H, Emoto M, Nishizawa Y. Pulse wave velocity in lower-limb arteries among diabetic patients with peripheral arterial disease. J Atheroscler Thromb. 2003. 10:253–258.
29. Ohnishi H, Saitoh S, Takagi S, Ohata J, Isobe T, Kikuchi Y, Takeuchi H, Shimamoto K. Pulse wave velocity as an indicator of atherosclerosis in impaired fasting glucose: the Tanno and Sobetsu study. Diabetes Care. 2003. 26:437–440.
30. Higashiura K, Ura N, Ohata J, Togashi N, Takagi S, Saitoh S, Murakami H, Takagawa Y, Shimamoto K. Correlations of adiponectin level with insulin resistance and atherosclerosis in Japanese male populations. Clin Endocrinol. 2004. 61:753–759.
31. Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation. 2007. 115:1528–1536.
32. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adioponectin concentration in patients with essential hypertension. Am J Hypertens. 2003. 16:72–75.
33. Fésüs G, Dubrovska G, Gorzelniak K, Kluge R, Huang Y, Luft FC, Gollasch M. Adiponectin is a novel humoral vasodilator. Cardiovasc Res. 2007. 75:719–727.
34. Mallamaci F, Zoccali C, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Adiponectin in essential hypertension. J Nephrol. 2002. 15:507–511.
35. Park YW, Allison DB, Heymsfield SB, Gallagher D. Larger amounts of visceral adipose tissue in asian american. Obes Res. 2001. 9:381–387.
37. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes. 2001. 50:1126–1133.
38. Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev. 2002. 3:141–146.
39. Unwin N, Harland J, White M, Bhopal R, Winocour P, Stephenson P, Watson W, Turner C, Alberti KG. Body mass index, waist circumference, waist-hip ratio, and glucose intolerance in Chinese and Europid adults in Newcastle, UK. J Epidermiol Community Health. 1997. 51:160–166.
40. Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, Hiuge A, Hibuse T, Ryo M, Nishizawa H, Maeda N, Maeda K, Shibata R, Walsh K, Funahashi T, Shimomura I. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension. 2006. 47:1108–1116.
XML Download